Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Abiraterone
Drug ID BADD_D00014
Description Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.
Indications and Usage Used in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer.
Marketing Status approved
ATC Code L02BX03
DrugBank ID DB05812
KEGG ID Not Available
MeSH ID C089740
PubChem ID 132971
TTD Drug ID D02STN
NDC Product Code 42291-024; 42291-073; 69238-1754; 60219-1754; 60687-455; 17337-0082; 54893-0070; 30007-838; 69238-1165; 60219-1165
UNII G819A456D0
Synonyms abiraterone | 17-(3-pyridyl)androsta-5,16-dien-3beta-ol | CB-7598 | CB 7598 | CB7598
Chemical Information
Molecular Formula C24H31NO
CAS Registry Number 154229-19-3
SMILES CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Transient ischaemic attack24.04.06.005; 17.08.04.0010.004271%
Trigeminal neuralgia17.04.08.0010.000334%Not Available
Ulcer08.03.06.0010.001068%Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urethral disorder20.07.01.002--Not Available
Urinary incontinence20.02.02.010; 17.05.01.008--
Urinary retention20.02.02.0110.006340%
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Uveitis10.02.01.023; 06.04.03.0030.000501%
Vasculitis24.12.04.027; 10.02.02.0060.000901%
Ventricular extrasystoles02.03.04.0070.000501%Not Available
Ventricular fibrillation02.03.04.0080.000834%
Vestibular disorder17.02.02.008; 04.04.02.0010.000334%
Vomiting07.01.07.003--
Mobility decreased15.03.05.023; 17.02.05.018; 08.01.03.030--Not Available
Musculoskeletal disorder15.03.05.0250.001068%Not Available
Cardiotoxicity02.11.01.009; 12.03.01.0070.001835%Not Available
Hypoacusis04.02.01.006--
Performance status decreased08.01.03.0420.000901%Not Available
Peripheral swelling08.01.03.053; 02.05.04.0150.024726%Not Available
Rectal discharge07.03.03.0050.001135%Not Available
Onychomadesis23.02.05.0060.000734%
General physical health deterioration08.01.03.0180.007374%Not Available
Tachyarrhythmia02.03.02.0080.000334%Not Available
Muscle fatigue15.05.03.0060.000734%Not Available
Muscle tightness15.05.03.0070.001702%Not Available
Balance disorder08.01.03.081; 17.02.02.0070.012446%Not Available
Dysstasia15.03.05.011; 08.01.03.089; 17.02.02.0120.001235%Not Available
Contusion15.03.05.007; 24.07.06.001; 23.03.11.002; 12.01.06.001--
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 12 Pages